5 assets in Skin Appendage Carcinoma

Therapeutic assets addressing Skin Appendage Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Skin Appendage Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Skin Appendage Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
mq719 Skin Appendage Carcinoma	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Pembrolizumab Skin Appendage Carcinoma	Memorial Sloan Kettering Cancer Center	P1	CC (43)
L19IL2/L19TNF Skin Appendage Carcinoma	Philogen S.p.A.	P2	NR ()